1	Original	article
---	----------	---------

3	Validation of the Panbio <sup>™</sup> COVID-19 Antigen Rapid Test (Abbott) to screen for SARS-
4	CoV-2 infection in Sint Maarten: a diagnostic accuracy study
5	
6	Authors: Colin King <sup>1</sup> , Eva Lista-de Weever <sup>1</sup> , Maria Henry <sup>1</sup> , Radjin Steingrover, PhD <sup>2</sup> ,
7	Chérina Fleming, PhD <sup>2</sup> , Richard Panneflek <sup>3</sup> , Sanne van Kampen, PhD <sup>1</sup> *
8	
9	Affiliations:
10	1. Collective Prevention Services, Ministry of Health, Social Development and Labor, Sint
11	Maarten
12	2. Department of Microbiology, St Maarten Laboratory Services, Sint Maarten
13	3. Ministerial Office, Ministry of Health, Social Development and Labor, Sint Maarten
14	
15	*Corresponding author:
16	Dr. Sanne Christine van Kampen
17	Collective Prevention Services
18	Ministry of Health, Social Development and Labor
19	W.G. Buncamper Road 33, Vineyard Building
20	Philipsburg, Sint Maarten
21	Email: Sanne.vankampen@sintmaartengov.org
22	Telephone: +17215249361
23	
24	Word count: 2,335
25	

#### 26 Abstract

27 Objectives: Control of the pandemic has required countries to look for other forms of tests 28 besides the gold standard real-time polymerase chain reaction (RT-PCR). Rapid antigen tests 29 (RAT), though less sensitive than RT-PCR, offer the possibility of rapid, inexpensive and 30 early detection of the most infectious COVID-19 cases. Only very few studies have assessed 31 the performance of the Abbott Panbio COVID-19 RAT among asymptomatic people or in 32 Latin America. This study set out to validate this test among people attending the public test 33 street in Sint Maarten, Dutch Caribbean. 34 35 Methods: People of all ages were recruited from the public COVID-19 test street regardless of 36 COVID-19 symptoms. They received a nasopharyngeal swab for the Abbott Panbio COVID-

37 19 RAT and the RT-PCR Qtower. Diagnostic accuracy of the RAT was compared to the RT-

38 PCR among the overall study population and for subgroups with/without symptoms,

39 with/without close contact and different Ct values.

40

41 Results: Using a RT-PCR Ct cut-off value of <33, 119 out of 1,411 people (8.4%) tested 42 positive for SARS-CoV-2. Most were asymptomatic (59%). The overall sensitivity and 43 specificity of the RAT was 84% (95% CI 76.2-90.1) and 99.9% (95% CI 99.6-100) respectively. 44 The sensitivity reduced to 67.6% (95% CI: 49.5%, 82.6%) among people without symptoms, 45 regardless of whether they were in close contact with a known COVID-19 case. Sensitivity 46 reduced considerably with a Ct cut-off value of <35.

47

48 Conclusions: The Abbott Panbio RAT is a valid and cheaper alternative to RT-PCR when

49 used on symptomatic individuals among the general population. However, among

- 50 asymptomatic people it should not be used as a stand-alone test and negative results should be
- 51 confirmed with RT-PCR.

#### 53 Introduction

54 Adequate and rapid diagnostics are essential for the treatment and control of COVID-19.<sup>1</sup>

55 The gold standard test to detect the SARS-CoV-2 virus is real-time polymerase chain reaction

56 (RT-PCR), a molecular assay targeting specific viral DNA.<sup>2</sup> In Sint Maarten, the public health

57 authorities use RT-PCR for SARS-CoV-2 testing to identify current infections in individuals

58 with signs or symptoms consistent with COVID-19. This testing is also used when an

59 asymptomatic person has been in contact with a SARS-CoV-2 positive case or identified by a

- 60 positive person through contact tracing.
- 61

62 While RT-PCR has optimal sensitivity and specificity to detect SARS-CoV-2, it is an 63 expensive technique that can only be performed in well-equipped laboratories with trained 64 laboratory staff. Control of the pandemic has required countries to look for other forms of 65 tests besides the standard RT-PCR. Rapid antigen tests (RAT), though less sensitive than RT-66 PCR, offer the possibility of rapid, inexpensive and early detection of the most infectious COVID-19 cases in appropriate settings.<sup>3</sup> RATs generally use an immunological lateral flow 67 assay to detect SARS-CoV-2 viral antigens.<sup>4</sup> RATs would be an appropriate alternative to 68 69 RT-PCR for many settings considering it would reduce the pressure on laboratories, while 70 also expanding testing capacity. A recent study from the Netherlands and Aruba found that 71 the Abbott Panbio COVID-19 RAT had a sensitivity of 87.4% and a specificity of 100% 72 among symptomatic people.<sup>5</sup> Only very few studies have assessed the performance of the 73 Abbott Panbio COVID-19 RAT among asymptomatic people or in Latin America and the Carribbean.<sup>67</sup> 74

- 76 This study set out to compare the Abbott Panbio COVID-19 RAT to the standard molecular
- 77 diagnostic assay RT-PCR among people who attended the public COVID-19 test street in Sint
- 78 Maarten, Dutch Caribbean, regardless of symptoms.
- 79

80 Methods

81

82 Study population and period

83 The study population consisted of people from the community of Sint Maarten, of all ages, 84 who voluntarily came to the public test street to receive a COVID-19 test. Participants were 85 enrolled from the 11th of January 2021 until the minimal required sample size was reached. 86 All persons were given verbal information about the testing procedure and were asked for 87 consent to participate in the study. Each person was tested with one nasopharyngeal swab for 88 RT-PCR and another nasopharyngeal swab for RAT by trained public health personnel. 89 People who did not receive two nasopharyngeal swabs, who tested positive for COVID-19 in 90 the past three months or did not consent to participate were not included in the study. 91 92 Diagnostic tests 93 **RT-PCR** test 94 The RT-PCR samples were sent to St Maarten Laboratory Services that operates an in-house 95 open PCR assay using a Q-tower amplification system targeting the SARS-CoV-2 E-gene. 96 Laboratory staff was trained on this system and the system was validated by the National 97 Institute for Public Health and the Environment of the Netherlands (RIVM). Amplification is 98 cut off at 35 cycles.

99

100 Rapid Antigen Test

101 The RAT selected was the Panbio Abbott COVID-19 Rapid Antigen Test. This is an

102 immunofluorescence-based lateral flow assay that can detect SARS-CoV-2 antigens within

103 15-30 minutes. This test fits the WHO criteria (sensitivity of  $\geq 80\%$ , specificity of  $\geq 97\%$ )<sup>8</sup> and

104 has been validated in the Netherlands among symptomatic persons.

105

106 Sample size calculation

107 Based on Buderer *et al.*,<sup>9</sup> a minimal required sample size was calculated to accurately

108 estimate the sensitivity and specificity of the RAT with a significance level of 5%. With an

109 estimated sensitivity of 80% and specificity of 97% (WHO's minimum requirements) and a

110 low estimated prevalence of disease of 5%, a minimum sample size of 1,230 participants was

estimated to provide a precision of 0.1 for the sensitivity's and specificity's 95% confidence

112 interval.

113

## 114 Analysis

Data was collected on demographics, clinical information and test results. Demographics
included contact details, age, sex, occupation, and house doctor. Clinical information included
COVID-19 symptoms, whether someone had been in close contact with a confirmed COVID19 patient and the last date of contact. Test results included results from the RT-PCR and
RAT tests. Participants with indeterminate or missing results were excluded from the study.
The study only collected personal data that was already routinely collected when people
attend the public health test street.

122

123 Participant characteristics were compared between people that tested positive and negative for

124 COVID-19 with RT-PCR. Differences in terms of age, sex, symptoms and close contact

125	between both groups were assessed using Pearson Chi-square tests (for proportions) and t-
126	tests (for means) using a significance level of $p=0.05$ .

128	To evaluate the accuracy of the Abbott Panbio COVID-19 RAT, RT-PCR was used as a
129	reference test to calculate the sensitivity, specificity, positive and negative predictive values
130	(PPV, NPV) with their confidence intervals at 95%. In this analysis, RT-PCR results were
131	considered positive if the cycle threshold (Ct) value for amplification of the E-gene was
132	below 33 cycles; and participants missing Ct values were removed. The clinical performance
133	of the RAT was stratified by asymptomatic and symptomatic persons as well as by people
134	with and without close contact to someone with COVID-19. Furthermore, a sensitivity
135	analysis of RAT accuracy was done using various Ct cut-off values for a positive PCR result.
136	All statistical calculations were performed in Stata and SPSS.
137	
138	Ethical approval
139	Ethical approval was requested from the Sint Maarten Medical Center (SMMC) Medical Ethics
140	Committee, who decided that ethical oversight was not required for this study.
141	
142	Results
143	
144	Population characteristics
145	From the 11th of January 2021 to the 26th of February 2021 a total of 1,507 participants were
146	recruited through the public health test street. Thirty participants (2%) had one or two missing
147	test results and were excluded from analysis.

Of the 1,477 individuals included in the study, the median age was 40.5 years (SD 16), most were female (59%), asymptomatic (59%) and had had no close contact with someone with COVID-19 (60%) (Table 1). Most commonly reported symptoms were headache (17%), cough (17%), runny/stuffy nose (17%), and sore throat (15%).

153

A total of 202 (14%) participants tested positive for SARS-CoV-2 with RT-PCR. Among them, the median age was 42.3 years (SD 16.2), most were female (65%) and had had no close contact (62%). An impressive 69% of positive participants reported symptoms. Symptoms significantly associated with testing positive for SARS-CoV-2 were fever, cough, loss of taste or smell, body ache (all p<0.00001) as well as runny/stuffy nose, headache, fatigue and shortness of breath (all p<0.05). Age and having been in close contact with a known COVID-19 case were unrelated.

160

## 161 Diagnostic accuracy

162 For the accuracy analysis, 66 participants were excluded because they had missing RT-PCR Ct 163 values. Of 1,411 people tested, 119 (8%) were positive by RT-PCR and 101 (7%) by RAT; 164 1,292 (92%) were negative by RT-PCR and 1,310 (93%) by RAT (Table 2). This resulted in an 165 overall performance of the RAT with a sensitivity of 84.0%, specificity of 99.9%, PPV of 99.9% and NPV of 98.5% (Table 3). Among people with symptoms, 15% were positive for COVID-166 167 19 by RT-PCR and the RAT had an increased sensitivity of 91%. Among people without symptoms, only 4% had COVID-19 and the sensitivity of the RAT decreased to 67.7%. The 168 169 performance of the RAT did not change when asymptomatic people had had close contact with 170 a known COVID-19 case. All subgroups had a specificity of at least 99.7%; a NPV of at least 171 98%; and PPV of at least 91.7%.

172

173 Sensitivity analyses

The diagnostic accuracy of the RAT compared to RT-PCR was analysed for Ct values of below 35, 30 and 25 (Table 4). Test sensitivity decreased as the Ct cut-off value increased. Especially when a Ct cut-off value of below 35 was used, meaning that samples with very low viral load were still considered positive, the sensitivity of the RAT decreased drastically. Specificity was at least 98.7% for all Ct cut-of values.

179

# 180 **Discussion**

181 This study found that among the general public of Sint Maarten, the Abbott Panbio COVID-182 19 RAT identified SARS-CoV-2 infected subjects with an overall sensitivity of 84.0% and 183 specificity of 99.9%. Most participants who attended the national test site were asymptomatic, 184 and half of the asymptomatic people had been in close contact with a COVID-19 positive 185 person. Compared to symptomatic people, the sensitivity was drastically lower among 186 asymptomatic people (67.6%) and below the minimally recommended sensitivity of 80% for a RAT as recommended by WHO and far below the 90% as recommended by ECDC.<sup>10</sup> The 187 NPV among this group remained at 98.7% due to the low prevalence of COVID-19. Although 188 189 there were slight variations in the specificity for different subgroups, it always stayed above 190 the recommended 97%.

191

The 84% overall sensitivity of the Abbott Panbio COVID-19 RAT estimated in this study was very similar to that found in studies using the same Ct cut-off value of <33. For example, two prospective studies in community testing sites in Switzerland and Germany found similar sensitivities of 89.7% and 88.3%, respectively.<sup>11</sup> Two studies in Spain that evaluated the Abbott Panbio RAT in primary health care centers reported lower overall sensitivities of 71.4% and 79.6% respectively, which may be due to the higher Ct cut-off value used.<sup>12 13</sup> A real-life validation of the Abbott Panbio RAT in the Netherlands found higher sensitivities of 95.2% at the study site in Utrecht and 98% in Aruba. This was a result of testing only
symptomatic people and using a lower Ct threshold for positive results. A recent study in the
Netherlands focused specifically on asymptomatic football players found an overall
sensitivity of 66.7%, which is very similar to the asymptomatic results from our study
(67.6%).<sup>14</sup> Despite the differences in sensitivity of the different studies, all had a specificity of
over 99%.

205

206 One strength of our study is that it is one of the first COVID-19 diagnostic accuracy studies in 207 the Caribbean, which provides insights into the potential performance of the Abbott Panbio 208 RAT for other Caribbean islands. The findings can also help different islands to decide on 209 how to best incorporate this test into their COVID-19 screening and diagnostic algorithms. 210 Furthermore, this is one of the first studies to specifically include an analysis of asymptomatic 211 participants and showed that it has low accuracy among this group. This may help countries to 212 prioritize this test for symptomatic people – especially those with fever, cough, loss of taste or 213 smell and body ache – and thereby ensure early detection and fast contact tracing of COVID-214 19 cases.

215

One limitation of this study was that it was unable to follow up persons before or after their test result. It is thus unknown whether PCR-positive persons were in the early or late stage of their infection and how the Abbott RAT performed in identifying people in their most contagious period. Further, symptoms were self-reported and may have been over- or underreported, which could have biased the difference in sensitivity between symptomatic and asymptomatic individuals.

223 One main implication of this study is that the Abbott RAT is not beneficial as a stand-alone 224 test for asymptomatic people as it will miss approximately one out of three people with 225 COVID-19 in this subgroup. The results show that approximately one out of ten positive 226 individuals with symptoms will not be spotted with the RAT, which makes it an acceptable 227 alternative for this subgroup. These findings confirm that COVID-19 RATs perform better among people with higher viral loads.<sup>15</sup> Based on these findings, the public health authorities 228 229 in Sint Maarten decided to perform the Abbott Panbio RAT among symptomatic people only, 230 while remaining to test all people attending the test street regardless of symptoms with RT-231 PCR.

232

233 In conclusion, the Abbott Panbio RAT is a valid and cheaper alternative to RT-PCR for

detecting COVID-19 when used on symptomatic individuals among the general population.

235 Taking into consideration the low cost, user-friendliness, and turnaround time, this test would

also be beneficial to identify clusters or outbreaks in specific settings when speed of results is

237 of essence. However, among asymptomatic people the Abbott Panbio RAT should not be used

as a stand-alone test and negative results should be confirmed with RT-PCR.

240	Conflict of interest
241	The authors declare to have no conflict of interest.
242	
243	Funding
244	The Abbott Panbio COVID-19 Rapid Antigen Tests were donated by the Ministry of Health,
245	Wellbeing and Sports of the Netherlands, for the purpose of this study. No other external
246	funding was received.
247	
248	Acknowledgements
249	The authors would like to thank the staff and volunteers of the testing team at the Department
250	of Collective Prevention Services of the Ministry of Health, Social Development and Labor of
251	Sint Maarten for conducting data collection and field testing with the Abbott Panbio COVID-
252	19 Rapid Antigen Test.
253	
254	Access to data
255	The full database is available upon reasonable request from the last author (SvK).
256	
257	Contributions
258	SvK, EdW, MH and RP conceptualized the study. SvK, RS and CF designed the
259	methodology. RS and CF conducted the laboratory tests. SvK and CK supported field testing
260	and data collection. CK conducted data validation, cleaning and analysis. CK wrote the first

- 261 draft manuscript. SvK supervised all aspects of the study. All authors reviewed and edited the
- 262 final manuscript.
- 263
- 264

Variable	Number (%) <sup>1</sup>	COVID-19 RT-	COVID-19	X2 test (p-
		PCR + (%)	RT-PCR –	value) <sup>2</sup>
			(%)	
Total	1,477 (100%)	202 (100)	1,275 (100	-
Age in years (mean, SD)	40.5 (16.3)	42.3 (16.2)	40.2 (16.3)	0.0912
Sex			•	
Male	608 (41.3)	69 (34.7)	539 (42.3)	0.041064
Female	864 (58.7)	130 (65.3)	734 (57.7)	-
Symptoms			•	
No symptoms	866 (59.2)	65 (32.3)	801 (63.5)	< 0.00001
With symptoms	596 (40.8)	139 (69.2)	460 (36.5)	-
Fever	160 (10.9)	47 (23.4)	113 (9.0)	< 0.00001
Cough	242 (16.6)	66 (32.8)	176 (14.0)	< 0.00001
Runny / stuffy nose	241 (16.5)	51 (25.4)	190 (15.1)	0.000255
Sore throat	221 (15.1)	38 (18.9)	183 (14.5)	0.106348
Shortness of breath	44 (3.0)	11 (5.5)	33 (2.6)	0.027753
Loss of taste or smell	79 (5.4)	45 (22.4)	34 (2.7)	< 0.00001
Headache	251 (17.2)	50 (24.9)	201 (15.9)	0.001808
Body ache	132 (9.0)	44 (21.9)	88 (7.0)	< 0.00001
Nausea / vomiting	48 (3.3)	6 (3.0)	42 (3.3)	0.798434
Diarrhea	38 (2.6)	6 (3.0)	32 (2.5)	0.711203
Fatigue / tiredness	99 (6.8)	22 (10.9)	78 (6.2)	0.01304
Other	81 (5.5)	15 (7.5)	66 (5.2)	0.199571
Close contact	•			•
Yes	517 (40.2)	67 (38.1)	450 (40.5)	0.540245
No	770 (59.8)	109 (61.9)	661 (59.5)	-

# 265 Table 1. Population characteristics of enrolled participants by COVID-19 status

266 Legend. RT-PCR: real-time polymerase chain reaction; X2: Chi-square; SD: standard

267 deviation. <sup>1</sup> Number of missing results by variable: age (7); sex (5); symptoms (15); close

268 contact (190).<sup>2</sup> For age, t-test was used.

269

# 270 Table 2. Diagnostics results among all participants (n=1,411) with PCR Ct cut-off of <33

	RT-PCR	Total	
RAT results (Abbott)	Positive	Negative	
Positive	100	1	101
Negative	19	1291	1310
Total	119	1292	1411

271 *Legend. RT-PCR: real-time polymerase chain reaction; RAT: rapid antigen test.* 

Participants	n	COVID-19	Prevalence	Sensitivity	Specificity	PPV (95%CI)	NPV (95%CI)
		RT-PCR +	(95%CI)	(95%CI)	(95%CI)		
All participants	1411	119	8.4%	84.0%	99.9%	99.0%	98.6%
			(7.0, 10.0)	(76.2, 90.1)	(99.6, 100)	(93.4, 99.9)	(97.8, 99.0)
With symptoms	550	84	15.3%	90.5%	100%	100%	98.3%
			(12.4, 18.6)	(82.1, 95.8)	(99.2, 100)		96.8, 99.1)
Without symptoms	846	34	4.0%	67.7%	99.9%	95.8%	98.7%
			(2.8, 5.6)	(49.5, 82.6)	(99.3, 100)	(76.2, 99.4)	(97.8, 99.2)
With close contact	370	17	4.6%	64.7%	99.7%	91.7%	98.3%
			(2.7, 7.3)	(38.3, 85.8)	(98.4, 100)	(60.1, 98.8)	(96.9, 99.1)
No close contact	374	13	3.5%	61.5%	100%	100%	98.6%
			(1.9, 5.9)	(31.6, 86.1)	(99.0, 100)		(97.3, 99.3)

Table 3. Diagnostics results for different subgroups, with PCR positive results with a cycle threshold cut-off of <33

273 Legend. RT-PCR: real-time polymerase chain reaction; CI: confidence interval.

274

# 275 Table 4. Diagnostic accuracy of rapid antigen test compared to RT-PCR with different Ct values as cut-off for positive results

RT-PCR positives	Number (%)	Prevalence% (95% CI)	Sensitivity% (95% CI)	Specificity% (95% CI)
Ct < 35	136 (100 %)	9.6% (8.1, 11.3)	73.5% (65.3, 80.7)	99.9% (99.6, 100)
Ct < 30	108 (79.4%)	7.7% (6.3, 9.17)	90.7% (83.6, 95.5)	99.8% (99.3, 100)
Ct < 25	86 (62.2%)	6.1% (4.9, 7.47)	97.7% (91.9, 99.7)	98.7% (98, 99.3)

276 Legend. . RT-PCR: real-time polymerase chain reaction; CI: confidence interval; Ct: cycle threshold.

## 277 **References**

278

<sup>1</sup> Dinnes J, Deeks JJ, Adriano A, Berhane S, Davenport C, Dittrich S, et al. Rapid, point-ofcare antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. 2020 Aug 26;2020(8). https://www/doi/10.1002/14651858.CD013705/full

<sup>2</sup> Vandenberg O, Martiny D, Rochas O, et al. Considerations for diagnostic COVID-19 tests.

Nat Rev Microbiol. 2020 Oct 14. https://doi.org/10.1038/s41579-020-00461-z

<sup>3</sup> World Health Organization. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays. Interim guidance, 11 September 2020. Available at: <u>https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-</u> <u>2infection-using-rapid-immunoassays</u>

<sup>4</sup> Panbio COVID-19 Ag Rapid Test Device | Abbott Point of Care Testing. Available from: <u>https://www.globalpointofcare.abbott/es/product-details/panbio-COVID-19-ag-antigen-</u> <u>test.html</u>

<sup>5</sup> Bonten. COVID-19: hoe betrouwbaar zijn sneltesten? Ned Tijdschr Geneeskd.

2020;164:C4678. Available at: https://www.ntvg.nl/artikelen/nieuws/COVID-19-hoe-

betrouwbaar-zijn-sneltesten/volledig

<sup>6</sup> Foundation for Innovative New Diagnostics (FIND). SARS-CoV-2 Diagnostics:

Performance data. Available at: https://www.finddx.org/COVID-19/dx-data/

<sup>7</sup> Rapid antigen tests for the diagnosis of a SARS-CoV-2 infection. University of Heidelberg,

Denmark, 2020. Available at: https://www.klinikum.uni-heidelberg.de/diagnostics-global-

<u>health</u>

<sup>8</sup> World Health Organization. Advice on the use of point-of-care immunodiagnostic tests for COVID-19: scientific brief. 8 April 2020. Available at:

# https://www.who.int/publications/i/item/advice-on-the-use-of-point-of-care-

immunodiagnostic-tests-for-COVID-19-scientific-brief

<sup>9</sup> Buderer NM. Statistical methodology: I. Incorporating the prevalence of disease into the sample size calculation for sensitivity and specificity. Acad Emerg Med. 1996;3(9):895–900.
<sup>10</sup> European Commission. Current performance of COVID-19 test methods and devices and proposed performance criteria. Working document of Commission services. Created by GROW.R.2.DIR. 17 April 2020. Available at:

https://ec.europa.eu/docsroom/documents/40805

<sup>11</sup> FIND Evaluation of Abbott Panbio COVID-19 Ag Rapid Test Device External Report

Version 2.1, 10 December 2020. Available at: <u>https://www.finddx.org/wp-</u> content/uploads/2020/12/Panbio\_Ag-Public-Report\_v2.1.pdf

<sup>12</sup> Bulilete O, Lorente P, Leiva A, Carandell E, Oliver A, Rojo E et al. Evaluation of the Panbio<sup>™</sup> rapid antigen test for SARS-CoV-2 in primary health care centers and test sites. medRxiv 2020. doi: <u>https://doi.org/10.1101/2020.11.13.20231316</u>

<sup>13</sup> Albert E, Torres I, Bueno F, Huntley D, Molla E, Fernández-Fuentes MÁ, Martínez M,

Poujois S, Forqué L, Valdivia A, Solano de la Asunción C, Ferrer J, Colomina J, Navarro D.

Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for

COVID-19 diagnosis in primary healthcare centres. Clin Microbiol Infect. 2021

Mar;27(3):472.e7-472.e10. doi: 10.1016/j.cmi.2020.11.004.

<sup>14</sup> Winkel, BMF, Schram E, Gremmels H, Debast SB, Schuurman R, Wensing AMJ, Bonten

MJM, Goedhart E, Hofstra, LM; Antigen Rapid Test Validation Group. Screening for SARS-

CoV-2 infection in asymptomatic individuals using the Panbio COVID-19 Antigen Rapid

Test (Abbott) compared to RT-qPCR. medRxiv 2020.

https://doi.org/10.1101/2020.12.03.20243311

<sup>15</sup> Beek JE , Igloi Z, Boelsums T, Fanoy E, Gotz H, Molenkamp R, Van Kampen J, Van

Kessel CG, Van der Eijk A, Van de Vijver D, Koopmans M. medRxiv 2020.

https://doi.org/10.1101/2020.10.13.20211524